DMRA
Damora Therapeutics, Inc.
21.30$
+3.0%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Cash Flow
All figures per share in USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| -13.46 | -19.00 | -37.81 | -51.77 | -42.24 | -34.73 | -16.09 | -4.93 | |
| – | 0.11 | 0.19 | 0.44 | 0.48 | 0.78 | 0.16 | 0.02 | |
| – | – | – | 4.43 | 5.48 | 5.11 | 2.80 | 0.73 | |
| -0.92 | 2.16 | -4.54 | -6.56 | 11.74 | -4.11 | -2.30 | 13.47 | |
| 0.00 | 0.00 | 0.00 | 0.22 | 0.19 | 0.00 | 0.00 | 0.00 | |
| – | -0.32 | – | -47.55 | 12.18 | 21.01 | 10.07 | -12.75 | |
| 42.14 | – | 185.45 | 0.00 | 0.50 | 2.71 | 0.00 | 195.78 | |
| 30.46 | -19.36 | 150.71 | -99.97 | -29.30 | -10.65 | -6.30 | 178.61 | |
| -13.46 | -19.00 | -37.81 | -51.99 | -42.43 | -34.73 | -16.09 | -4.93 |
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.